Skip to main content

Table 1 Clinical characteristics of 262 patients with IPF treated with antifibrotic therapy

From: Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study

 

Switch-IPF cohort (n = 37)

Non-Switch-IPF cohort (n = 225)

Non-Switch-IPF Continued cases (n = 177)

Non-Switch-IPF Discontinued cases (n = 48)

Non-Switch IPF versus Switch-IPF

p value

Age, years

70.0 [65.5–74.0]

73.0 [68.0–77.0]

72.0 [67.5–76.0]

74.0 [68.0–79.0]

0.0616

Sex, male/female

31 (83.8%)/6 (16.2%)

185 (82.2%)/40 (17.8%)

147 (83.0%)/30 (17.0%)

38 (79.2%)/10 (20.8%)

1.000

cIPF/UIP/IPF

31 (83.8%)/6 (16.2%)

175 (77.8%)/50 (22.2%)

134 (75.7%)/43 (24.3%)

41 (85.4%)/7 (14.6%)

0.5186

Diagnosis to antifibrotic therapy, months

13.6 [1.7–31.5]

15.4 [2.8–47.2]

12.1 [2.6–44.1]

31.5 [5.6–66.1]

0.2324

Pirfenidone/Nintedanib

29 (78.4%), 8 (21.6%)

130 (57.8%), 95 (42.2%)

102 (57.6%)/75 (42.4%)

28 (58.3%)/ 20 (41.7%)

0.0184

History of AE

0 (0%)

33 (14.7%)

25 (14.1%)

8 (16.7%)

0.0067

Never/former & current smoker

6 (16.2%), 31 (83.8%)

46 (20.4%), 179 (79.6%)

37 (20.9%)/140 (79.1%)

9 (18.8%)/39 (81.3%)

0.6602

Smoking pack-year

40.0 [18.0–59.0]

30.0 [3.0–46.0]

30.8 [3.0–45.0]

30.0 [7.5–48.0]

0.1297

BMI, kg/m2

24.3 [21.3–25.3]

22.9 [20.7–25.4]

23.3 [21.4–25.7]

21.9 [19.5–23.5]

0.2329

Pulmonary function test

FVC, %-pred

73.2 [62.4–83.7]

67.7 [56.5–79.8]

68.3 [58.5–80.2]

61.4 [47.7–77.4]

0.1018

FEV1, %-pred

75.3 [67.6–87.6]

74.4 [63.3–92.2]

76.4 [64.5–90.9]

73.1[55.8–90.9]

0.7480

FEV1/FVC, %

83.4 [79.9–88.9]

86.4 [79.9–92.2]

85.4 [79.8–91.4]

90.2 [80.4–94.5]

0.0438

DLCO, %

62.2 [50.2–67.6] (n = 37)

58.3 [43.4–72.0] (n = 185) Unable to perform (n = 14)

58.4 [44.0–71.5] (n = 153) Unable to perform (n = 7)

57.6 [38.1–77.7] (n = 32) Unable to perform (n = 7)

0.3516

GAP stage, I, II, III

18 (48.6%), 19 (51.4%), 0 (0%)

76 (38.2%), 90 (45.2%), 33 (16.6%)

63 (39.4%), 74 (46.3%), 23 (14.4%)

13 (33.3%), 16 (41.0%), 10 (25.6%)

0.0267

6-min walk test

Distances, m

432 [345–515] (n = 28)

400 [310–484] (n = 134)

400 [308–484] (n = 116)

400 [180–482] (n = 18)

0.1990

Minimum SpO2 < 90%

19/28 (67.9%)

100/134 (74.6%)

87/116 (75.0%)

13/18 (72.2%)

0.4845

UCG

TRV ≥ 2.9 m/s

2 (8.7%) (n = 29)

24 (17.9%) (n = 134)

16 (15.4%) (n = 104)

8 (26.7%) (n = 30)

0.1719

Laboratory

     

Hb, g/dl

14.0 [13.2–15.1]

13.5 [12.3–14.7]

13.6 [12.4–14.8]

13.3 [12.1–14.7]

0.0612

TP, g/dl

7.5 [7.2–7.9]

7.4 [6.9–7.8]

7.5 [7.0–7.8]

7.3 [6.7–7.8]

0.0855

Alb, g/dl

4.1 [4.0–4.2]

3.9 [3.6–4.1]

3.9 [3.6–4.1]

3.7 [3.5–4.0]

0.0006

LDH, U/L

241 [210–270]

230 [203–273]

228 [203–268]

244 [206–280]

0.8415

CRP, mg/dl

0.2 [0.1–0.5]

0.3 [0.1–0.6]

0.3 [0.1–0.6]

0.3 [0.1–0.6]

0.5156

KL-6, U/ml

1124 [776–1473]

1062 [798–1524]

1057 [796–1560]

1105 [817–1402]

0.7003

SP-D, ng/ml

232 [136–345]

249 [165–370]

247 [158–375]

251 [188–369]

0.7278

Treatment

None

30 (81.1%)

128 (56.9%)

126 (71.2%)

22 (45.8%)

0.0060

LTOT

6 (16.2%)

85 (37.8%)

65 (36.7%)

20 (41.7%)

0.0144

Flow rate during rest

< 1, 1–3, > 3, L/min

4, 2, 0

40, 42, 3

30, 32, 3

10, 10, 0

 

Immunosuppressants

3 (8.1%)

50 (22.2%)

37 (20.9%)

13 (27.1%)

0.0486

 PSL

3

30

23

8

 

 PSL + CyA

0

11

7

4

 

 PSL + CPA

 

5

3

2

 

 PSL + Tac

 

4

4

0

 
  1. AE acute exacerbation, BMI body mass index, FVC forced vital capacity, FEV1.0 forced expiratory volume in 1.0 s, DLCO diffuse capacity of the lung for carbon monoxide, GAP Gender–Age–Physiology, UCG ultrasound echocardiogram, TRV Tricuspid regurgitant jet velocity, KL-6 Krebs von den Lunge-6, SP-D surfactant protein-D, LTOT long-term oxygen therapy, PSL prednisolone, CyA cyclosporine A, CPA cyclophosphamide, Tac tacrolimus